PARIS, LONDON, MUNICH, NEW YORK: 20 February, 2019 – Bryan, Garnier & Co, a leading pan-European investment banking partnership focusing on growth companies, today announces that Pierre Kiecolt-Wahl is to become a Partner at the firm.

Pierre Kiecolt-Wahl, a dual American/French citizen joined Bryan, Garnier & Co’s European investment banking team as Managing Director, heading up the Equity Capital Markets division in May 2016. Pierre brings over 15 years of international equity capital markets knowledge with organizations such as Bank of America, Lehman Brothers, Jefferies and Citi, based in San Francisco, London and Hong Kong.

Since arriving at Bryan, Garnier & Co, he has led numerous transactions, continuing to strenghthen the firm’s footprint across Europe and the US. Key transactions include: Zealand Pharma Wall-Crossed Follow-On Offering (DKK 143m) | Symetis Euronext IPO & subsequent sale to Boston Scientific ($435m), Celyad Nasdaq & Euronext Publicly Marketed Follow-on Offering (€46m) | Ablynx Nasdaq IPO ($230m) | Medartis Six Swiss IPO (CHF 143m) | Canopy Growth Global Convertible Bond, Toronto Stock Exchange (CAD 600m) and Materialise’s Nasdaq Follow-on Offering ($45m).

Olivier Garnier, Co-founder & Managing Partner comments: “We are excited to welcome Pierre into the Bryan Garnier partnership, one of the few remaining independent investment banking partnerships in Europe. This makes us very special. Since founding the bank over 22 years ago, our business model has created a strong entrepreneurial culture that truly aligns us with the interest of our clients which Pierre has embraced. The personal commitment of our partners to the firm ensures a long-term perspective in building Bryan, Garnier & Co and our clients know they can count on us to stay the course with them as their business grows. We would like to congratulate Pierre for becoming Partner to Bryan, Garnier & Co. This is a very exciting time for the firm and we wish Pierre every success in his new role.”